Phathom Pharmaceuticals
OverviewSuggest Edit
Phathom Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases and disorders. The company offers Vonoprazan, a small molecule potassium-competitive acid blocker to treat gastroesophageal reflux disease, including erosive esophagitis, gastric and duodenal ulcer, and low dose aspirin-associated ulcer.
| Type | Public | |
| Founded | 2018 | |
| HQ | Buffalo Grove, IL, US | Map |
| Website | phathompharma.com |
Recent NewsAll News
- Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
- Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
- Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
- Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
Key People/Management at Phathom Pharmaceuticals
Tadataka Yamada
Chairman
Terrie Curran
President, Chief Executive Officer & Director
Azmi Nabulsi
Chief Operating Officer
Joe Hand
Chief Administrative Officer
Michael Cola
Director
Aditya Kohli
Chief Business Officer
Phathom Pharmaceuticals Office Locations
Phathom Pharmaceuticals has offices in Buffalo Grove, Florham Park and Menlo Park
Buffalo Grove, IL, US (HQ)
2150 E Lake Cook Rd #800Buffalo
Florham Park, NJ, US
100 Campus Dr #102
Menlo Park, CA, US
70 Willow Rd
Phathom Pharmaceuticals Financials and Metrics
Phathom Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (FY, 2020) | (129.1m) |
EBIT (FY, 2020) | (125.7m) |
Market capitalization (22-Jul-2021) | 1.0b |
Closing stock price (22-Jul-2021) | 32.7 |
Cash (31-Dec-2020) | 287.5m |
EV | 783.3m |
Phathom Pharmaceuticals's current market capitalization is $1 b.
Annual
Annual
Phathom Pharmaceuticals Operating Metrics
Show all operating metricsPhathom Pharmaceuticals Cybersecurity Score
Phathom Pharmaceuticals Environment, Social & Governance (ESG) Ratings
Phathom Pharmaceuticals Online and Social Media Presence
Phathom Pharmaceuticals's Trends
Phathom Pharmaceuticals News and Updates
May 11, 2021
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
FLORHAM PARK, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 202…
April 29, 2021
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that in PHALCON-HP, its pivotal Phase 3 cli…
April 06, 2021
Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will pa…
January 19, 2021
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in …
December 16, 2020
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offer…
December 14, 2020
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET) Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM…
Phathom Pharmaceuticals Frequently Asked Questions
When was Phathom Pharmaceuticals founded?
Phathom Pharmaceuticals was founded in 2018.
Who are Phathom Pharmaceuticals key executives?
Phathom Pharmaceuticals's key executives are Tadataka Yamada, Terrie Curran and Azmi Nabulsi.
How many employees does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 16 employees.
Who are Phathom Pharmaceuticals competitors?
Competitors of Phathom Pharmaceuticals include Restech, Neopharmed Gentili and Abiogen Pharma.
Where is Phathom Pharmaceuticals headquarters?
Phathom Pharmaceuticals headquarters is located at 2150 E Lake Cook Rd #800Buffalo, Buffalo Grove.
Where are Phathom Pharmaceuticals offices?
Phathom Pharmaceuticals has offices in Buffalo Grove, Florham Park and Menlo Park.
How many offices does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies